medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2007, Número 11

<< Anterior Siguiente >>

Ginecol Obstet Mex 2007; 75 (11)


Osteonecrosis mandibular asociada a bisfosfonatos

Carranza LS

Idioma: Español
Referencias bibliográficas: 44
Paginas: 655-660
Archivo PDF: 121.08 Kb.


RESUMEN

Introducción: la osteonecrosis mandibular es un padecimiento relacionado con el tratamiento con bisfosfonatos potentes, con una prevalencia de 1 a 10% en pacientes con cáncer.
Objetivo: revisar la bibliografía relacionada con la osteonecrosis mandibular y determinar el estado actual de este padecimiento.
Método: con el auxilio del MEDLINE se buscaron y revisaron los artículos publicados sobre el tema hasta el 18 de septiembre de 2007. Se cruzaron las siguientes palabras: bisfosfonatos, alendronato, ácido clodrónico, etidronato, ibandronato, risedronato, osteonecrosis y mandíbula. Se obtuvieron 114 referencias y se seleccionaron las más relevantes.
Resultados: la osteonecrosis mandibular se manifiesta de diversas maneras: edema gingival masivo con o sin exposición de hueso necrótico en la cavidad oral, acompañado de dolor intenso o puede ser asintomática. Los síntomas pueden remedar problemas dentales comunes, como: caries o enfermedad periodontal. La osteonecrosis mandibular puede manifestarse espontáneamente o posterior a la extracción de una pieza dentaria. Existen varias teorías para explicarla, pero hasta el momento no hay alguna del todo satisfactoria. El diagnóstico se realiza, principalmente, con base en los antecedentes: edad (séptima década de la vida), aplicación de bisfosfonatos intravenosos, tratamiento prolongado con los mismos, cáncer, extracción dental y quimioterapia. El tratamiento puede ser variable.
Conclusión: los bisfosfonatos de potencia elevada y larga duración se relacionan con más riesgo de osteonecrosis mandibular, aunque debe mantenerse una vigilancia estrecha en los prescritos para osteoporosis.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Bolland M, Hay D, Grey A, Reid I, Cundy T. Osteonecrosis of the jaw and bisphosphonates--putting the risk in perspective. N Z Med J 2006;119(1246):U2339.

  2. Van Poznak C, Estilo C. Osteonecrosis of the jaw in cancer patients receiving IV bisphosphonates. Oncology (Williston Park) 2006;20:1053-62.

  3. Walter C, Grotz KA, Kunkel M, Al-Nawas B. Prevalence of bisphosphonate associated osteonecrosis of the jaw within the field of osteonecrosis. Support Care Cancer 2007 15:197-202.

  4. Khosa AD, Nayyar MS, Beirne JC. Osteochemonecrosis of jaws and bisphosphonates. Ir Med J 2007;100:410-11.

  5. Pozzi S, Marcheselli R, Sacchi S, Baldini L, Angrilli F, Pennese E, et al. Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients. Leuk Lymphoma 2007;48:56-64.

  6. Zavras AI, Zhu S. Bisphosphonates are associated with increased risk for jaw surgery in medical claims data: is it osteonecrosis? J Oral Maxillofac Surg 2006;64:917-23.

  7. Hellstein JW, Marek CL. Bisphosphonate osteochemonecrosis (bis-phossy jaw): is this phossy jaw of the 21st century? J Oral Maxillofac Surg 2005;63:682-89.

  8. Abu-Id MH, Acil Y, Gottschalk J, Kreusch T. Bisphosphonatassoziierte Osteonekrose des Kiefers.Mund Kiefer Gesichtschir 2006;10:73-81.

  9. Capalbo S, Delia M, Diomede D, Dargenio M, Chiefa A, Favia G, et al. Jaw osteonecrosis associated with use of bisphosphonates and chemotherapy: paradoxical complication of treatment of bone lesions in multiple myeloma patients. Int J Hematol 2006;83:439-42.

  10. Merigo E, Manfredi M, Meleti M, Corradi D, Vescovi P. Jaw bone necrosis without previous dental extractions associated with the use of bisphosphonates (pamidronate and zoledronate): a four-case report. J Oral Pathol Med 2005;34:613-17.

  11. Wang EP, Kaban LB, Strewler GJ, Raje N, Troulis MJ. Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy. J Oral Maxillofac Surg 2007;65:1328-31.

  12. Migliorati CA, Siegel MA, Elting LS. Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. Lancet Oncol 2006;7:508-14.

  13. Najm SA, Lysitsa S, Carrel JP, Lesclous P, Lombardi T, Samson J. Osteonecrose des maxillaires chez des patients traites par bisphosphonates.Presse Med 2005;34:1073-77.

  14. Aspenberg P. Osteonecrosis of the jaw: what do bisphosphonates do? Expert Opin Drug Saf 2006;5:743-45.

  15. Ardine M, Generali D, Donadio M, Bonardi S, Scoletta M, Vandone AM, et al. Could the long-term persistence of low serum calcium levels and high serum parathyroid hormone levels during bisphosphonate treatment predispose metastatic breast cancer patients to undergo osteonecrosis of the jaw? Ann Oncol 2006;17:1336-37.

  16. Gering A, Grange L, Villier C, Woeller A, Mallaret M. Les osteonecroses de la machoire associees aux biphosphonates: synthese bibliographique. Therapie 2007;62:49-54.

  17. Van den Wyngaert T, Huizing MT, Vermorken JB. Bisphosphonates and osteonecrosis of the jaw: cause and effect or a post hoc fallacy? Ann Oncol 2006;17:1197-204.

  18. Badros A, Weikel D, Salama A, Goloubeva O, Schneider A, Rapoport A, et al. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 2006;24:945-52.

  19. Phal PM, Myall RW, Assael LA, Weissman JL. Imaging findings of bisphosphonate-associated osteonecrosis of the jaws. AJNR Am J Neuroradiol 2007;28:1139-45.

  20. Bianchi SD, Scoletta M, Cassione FB, Migliaretti G, Mozzati M. Computerized tomographic findings in bisphosphonate-associated osteonecrosis of the jaw in patients with cancer. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007;104:249-58.

  21. Sanna G, Preda L, Bruschini R, Cossu Rocca M, Ferretti S, Adamoli L, et al. Bisphosphonates and jaw osteonecrosis in patients with advanced breast cancer. Ann Oncol 2006;17: 1512-16.

  22. Bagán J, Blade J, Cozar JM , Constela M, García Sanz R, Gómez Veiga F, et al. Recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw (ONJ) in cancer patients treated with bisphosphonates Med Oral Patol Oral Cir Bucal 2007;12:E336-40.

  23. Junod AF, Carrel JP, Richter M, Vogt-Ferrier N. Osteonecrose des maxillaires et bisphosphonates. Rev Med Suisse 2005;1:2537-40.

  24. Murad OM, Arora S, Farag AF, Guber HA. Bisphosphonates and osteonecrosis of the jaw: a retrospective study. Endocr Pract 2007;13:232-38.

  25. Freiberger JJ, Padilla-Burgos R, Chhoeu AH, Kraft KH, Boneta O, Moon RE, et al. Hyperbaric oxygen treatment and bisphosphonate-induced osteonecrosis of the jaw: a case series. J Oral Maxillofac Surg 2007;65:1321-27.

  26. Landesberg R, Wilson T, Grbic JT. Bisphosphonate-associated osteonecrosis of the jaw: conclusions based on an analysis of case series. Dent Today 2006;25:52, 54-7.

  27. Weitzman R, Sauter N, Eriksen EF, Tarassoff PG, Lacerna LV, Dias R, et al. Critical review: Updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients—May 2006 Critical Reviews in Oncology/Hematology 2007;62:148-52.

  28. Zarychanski R, Elphee E, Walton P, Johnston J. Osteonecrosis of the jaw associated with pamidronate therapy. Am J Hematol 2006;81:73-5.

  29. Kademani D, Koka S, Lacy MQ, Rajkumar SV. Primary surgical therapy for osteonecrosis of the jaw secondary to bisphosphonate therapy. Mayo Clin Proc 2006;81:1100-103.

  30. Nase JB, Suzuki JB. Osteonecrosis of the jaw and oral bisphosphonate treatment. J Am Dent Assoc 2006;137:1115-19.

  31. Dannemann C, Gratz KW, Riener MO, Zwahlen RA. Jaw osteonecrosis related to bisphosphonate therapy: a severe secondary disorder. Bone 2007;40:828-34.

  32. Pickett FA. Bisphosphonate-associated osteonecrosis of the jaw: a literature review and clinical practice guidelines. J Dent Hyg 2006;80:10.

  33. Krueger CD, West PM, Sargent M, Lodolce AE, Pickard AS. Bisphosphonate-induced osteonecrosis of the jaw. Ann Pharmacother 2007;41:276-84.

  34. Koka S, Clarke BL, Amin S, Gertz M, Ruggiero SL. Oral bisphosphonate therapy and osteonecrosis of the jaw: what to tell the concerned patient. Int J Prosthodont 2007;20:115-22.

  35. Ruggiero SL, Mehrota B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004;62: 527-34.

  36. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005;23:8580-87.

  37. Calvo-Villas JM, Tapia Torres M, Govantes Rodriguez J, Carreter de Granda E, Sicilia Guillen F. Osteonecrosis del maxilar en pacientes con mieloma multiple durante y despues del tratamiento con acido zoledronico. Med Clin (Barc) 2006;127:576-79.

  38. Shimura K, Shimazaki C, Taniguchi K, Akamatsu S, Okamoto M, Uchida R, et al. Hyperbaric oxygen in addition to antibiotic therapy is effective for bisphosphonate-induced osteonecrosis of the jaw in a patient with multiple myeloma. Int J Hematol 2006;84:343-45.

  39. Zervas K, Verrou E, Teleioudis Z, Vahtsevanos K, Banti A, Mihou D, et al. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. Br J Haematol 2006;134:620-23.

  40. Dimopoulos MA, Kastritis E, Anagnostopoulos A, Melakopoulos I, Gika D, Moulopoulos LA, et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica 2006;91:968-71.

  41. Thakkar SG, Isada C, Smith J, Karam MA, Reed J, Tomford JW, et al. Jaw complications associated with bisphosphonate use in patients with plasma cell dyscrasias. Med Oncol .2006; 23:51-6.

  42. Montazeri AH, Erskine JG, McQuaker IG. Oral sodium clodronate induced osteonecrosis of the jaw in a patient with myeloma. Eur J Haematol 2007;79:69-71.

  43. Ortega C, Montemurro F, Faggiuolo R, Vormola R, Nanni D, Goia F, et al. Osteonecrosis of the jaw in prostate cancer patients with bone metastases treated with zoledronate: a retrospective analysis. Acta Oncol 2007;46:664-68.

  44. Clarke BM, Boyette J, Vural E, Suen JY, Anaissie EJ, Stack BC. Bisphosphonates and jaw osteonecrosis: the UAMS experience. Otolaryngol Head Neck Surg 2007;136:396-400.




2020     |     www.medigraphic.com